Imugene (ASX:IMU) Leslie Chong, CEO & Managing Director has presented at The Stock Network's ASX Gems Investment Conference: Healthcare Spotlight. Click here to watch what next in 2026⚡ https://youtu.be/aGcUWeuv--U | The Stock Network
0:26
Imugene (ASX:IMU) Leslie Chong, CEO & Managing Director has pre…
4 views1 month ago
FacebookThe Stock Network
Imugene with Proactive at ASX Small and Mid Cap Conference
Imugene with Proactive at ASX Small and Mid Cap Conference
Mar 26, 2024
proactiveinvestors.com.au
Imugene teams with ABL to bring VAXINIA into next clinical chapter
Imugene teams with ABL to bring VAXINIA into next clinical chapter
Oct 18, 2022
proactiveinvestors.com.au
Imugene doses first patient for VAXINIA bile tract cancer trial in Melbourne
Imugene doses first patient for VAXINIA bile tract cancer trial in M…
Jul 9, 2024
proactiveinvestors.com
Imugene to open new PD1-Vaxx Phase 2 bowel cancer clinical trial in UK and Australia
Imugene to open new PD1-Vaxx Phase 2 bowel cancer clinical trial …
Dec 5, 2023
proactiveinvestors.com.au
S&P/ASX 300 Chart - Investing.com AU
S&P/ASX 300 Chart - Investing.com AU
Aug 22, 2015
investing.com
Imugene well positioned to deliver 2024 milestones
Imugene well positioned to deliver 2024 milestones
Dec 29, 2023
proactiveinvestors.com.au
Imugene opens enrolment for Bile Tract Cancer expansion study
Apr 14, 2024
proactiveinvestors.com.au
Imugene thrilled as VAXINIA granted FDA Fast Track designation
Nov 27, 2023
proactiveinvestors.com.au
Imugene off to strong start to 2023 with JP Morgan Healthcare Confer…
Jan 22, 2023
proactiveinvestors.com.au
Imugene sees positive early signals in Phase 1 VAXINIA study
Nov 6, 2023
proactiveinvestors.com.au
Imugene seeks to activate immune system of cancer patients to identi…
Jul 23, 2022
proactiveinvestors.com.au
Imugene In Deal With Merck KGaA, Pfizer To Evaluate HER-Vaxx - Ave…
Nov 17, 2021
nasdaq.com
Imugene doses first patient in VAXINIA IV cohort 2 trials
Dec 5, 2022
proactiveinvestors.com.au
Imugene secures IND approval for first-in-class onCARlytics trial
May 19, 2023
proactiveinvestors.com
Imugene’s Phase 1 onCARlytics clinical trial doses first patient in i…
Feb 14, 2024
proactiveinvestors.com.au
Imugene and Kincell Bio form manufacturing and process devel…
Apr 16, 2024
proactiveinvestors.com.au
Imugene wins US FDA approval to begin onCARlytics first-in-class cl…
May 19, 2023
proactiveinvestors.com
Imugene records positive final safety and efficacy data from Phas…
Jun 27, 2022
proactiveinvestors.com.au
Imugene partners with Kincell Bio; selling cell therapy manufacturin…
Apr 16, 2024
proactiveinvestors.com
Imugene doses first patient in IV arm of Phase 1 onCARlytics trial t…
Jun 23, 2024
proactiveinvestors.com.au
Imugene sees positive early signs in VAXINIA trial; “may be potent anti …
Nov 6, 2023
proactiveinvestors.com.au
Imugene opens higher as novel cancer-killing virus VAXINIA is gra…
Nov 27, 2023
proactiveinvestors.com.au
Imugene says Azer-cel could be best-in-class Allogeneic CAR T
3 viewsNov 13, 2023
proactiveinvestors.com
Imugene advances to combination dosing with Phase 1 onCARlytics …
Mar 11, 2024
proactiveinvestors.com.au
Imugene expands bile tract cancer study as patient shows complete r…
Apr 15, 2024
proactiveinvestors.com
Imugene doses first patient in intravenous monotherapy arm of …
Feb 14, 2024
proactiveinvestors.com
Imugene targets defender B-cells with cancer vaccines HER-Vaxx a…
Feb 12, 2019
proactiveinvestors.com
Imugene raises A$18.2 million in SPP for acquisition of Azer-cel lic…
Sep 25, 2023
proactiveinvestors.com.au
Imugene fields positive results in Phase 1b trial of azer-cel CAR T th…
Sep 2, 2024
proactiveinvestors.com.au
See more videos
Static thumbnail place holder